Background: Although several dexamethasone phosphate preparations are commercially available and frequently administered with octreotide acetate, their compatibility remains unknown. Aim: We investigated the effect of pH and sodium bisulphate on the stability of octreotide acetate. Measurement design: Octreotide acetate percentage was measured 3 and 10 days after it was mixed with 2 dexamethasone phosphate preparations containing different concentrations of sodium bisulphate as an additive, and in one that did not contain sodium bisulphate. Solutions were also analysed after they were prepared using phosphate buffer to achieve pH values of 4.0, 7.0, and 9.0. The initial octreotide acetate concentration was 41.7 g/mL. High−performance liquid chromatography was used for measurement. Results: The octreotide acetate percentage in the mixture with dexamethasone phosphate without sodium bisulphate was maintained at 95% for up to 10 days. However, mixing octreotide acetate with the other 2 agents resulted in a significant decrease to 85%. The octreotide acetate percentage was ＜90% after sodium bisulphate−containing solution was stored at room temperature under light−protected conditions for 3 days. The percentage of octreotide acetate in the pH 7.0 solution was ＜90% three days after preparation; however, in the pH 4.0 solution, it was maintained at 95% for up to 10 days. Conclusions: Our results suggest that octreotide acetate is hydrolysed in the presence of sodium bisulphate, leading to a decrease in the percentage of octreotide acetate in the solution, which can be avoided using sodium bisulphate−free dexamethasone phosphate preparations. Palliat Care Res 2013; 8(2): 177−83
Introduction
Octreotide acetate (OCT) is a cyclic octapeptide containing a disulphide bond that is necessary for the physiological activities of the molecule ( Fig. 1) 
1-3)
. It is a key drug for cancerous, peritonitis−related obstruction of the digestive tract 4, 5) . In terminal cancer patients with obstruction of the digestive tract, early combination therapy with OCT and dexamethasone sodium phosphate (DEX) reduces oedema of the digestive tract, decreasing digestive tract pressure and relieving obstruction 6) . These 2 agents are frequently administered together for palliative care.
Sodium bisulphate (SBS) is an additive contained in some DEX injection preparations and has been reported to inactivate physiologically active peptides through peptide hydrolysis or disulphide bond cleavage 7, 8) . However, this change cannot be evaluated visually. In addition, no study has examined the compatibility of OCT with DEX injection in the absence of SBS. Whether DEX preparations contain SBS differs between countries. In Japan, SBS−containing and SBS−free DEX preparations are both commercially available.
It has been reported that continuous subcutaneous administration of OCT and other drugs in a mixture is useful for the patients who cannot take the drugs orally 9) . Currently, limited information is available regarding the stability of OCT mixed with other drugs including DEX injection preparations, excluding diamorphine hydrochloride 10) ; this information is necessary for estimating compatibility. In combination therapy with OCT and DEX, recommendations specify that DEX should be subcutaneously administered separately from OCT 11) .
However, given that frequent punctures reduce quality of life (QOL), identifying the causes of incompatibility and investigating methods that may allow them to be injected as a mixture may be beneficial to patients. In this study, both SBS−containing and SBS−free DEX injection preparations were mixed with OCT, and the concentration of OCT was quantified using high−performance liquid chromatography (HPLC) to evaluate the effect of SBS on the stability of OCT mixed with DEX injection preparations. The effect of pH on the stability of the mixtures was also investigated because of an important factor influencing a hydrolysis reaction 12) .
Methods 1 Materials
OCT was obtained from Sigma−Aldrich Japan (Japan). Sand- All of the other chemicals used were reagent grade and commercially available.
OCT preparations
To determine the experimental conditions, the daily doses of OCT and DEX were assumed to be 300 μg and 4.0 mg, respectively. Based on continuous S.C. administration for 7 days at a flow velocity of 0.3 mL/h 13) , the final concentrations of OCT and DEX were established as 41.7 μg/mL and 0.556 mg/mL, respectively. 1. Compatibility study with commercially available preparations OCT was mixed with 3 DEX preparations (DEX−SBS 2.0, DEX−SBS 0.5, and DEX−SBS 0) and diluted with physiological saline to achieve concentrations of OCT and DEX that were 41.7 μg/mL and 0.556 mg/mL, respectively. In these preparations, the final SBS concentrations in the mixed samples containing DEX−SBS 2.0, DEX−SBS 0.5, and DEX−SBS 0 were 0.278, 0.0694, and 0 mg/mL, respectively.
For consistency with conditions used in clinical practice, pH was not adjusted. Each sample was stored in a 1.5 mL microtube (Promega, Tokyo, Japan) under light−protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.
Effect of pH
Each sample was diluted to an OCT concentration of 41.7 μg/mL with phosphate buffer at pH values of 4.0, 7.0, and 9.0. The pH was adjusted with sodium dihydrogen phosphate solution and disodium hydrogen phosphate. Each sample was stored in a 1.5 mL microtube (Promega) at room temperature under light−protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.
Effect of SBS
To exclude the effect of pH, a solution containing 45 mg D−mannitol and 3.4 mg/mL lactic acid was mixed with saturated sodium hydrogen carbonate solution so that the pH value was 4.2 (OCT vehicle);
this solution was used to dilute OCT. The composition of the OCT vehicle was similar to that of Sandostatin Ⓡ excluding OCT. We investigated the stability of OCT when SBS−free control and SBS−containing (concentration of SBS: 0.3 mg/mL) samples were stored at room temperature or in a cool place (4°C). In these samples, the concentration of OCT was 41.7 μg/mL. Each sample was stored in a 1.5−mL microtube (Promega) under light−protected conditions, and the percentage of OCT in the sample was measured after 3 and 10 days.
HPLC analysis
For HPLC analysis 14) , we used an LC−2010CHT HPLC system 
Assay line
OCT was diluted with the OCT vehicle for the preparation of a specific volume of standard solutions (OCT concentrations: 1, 5, 10, 20, and 50 μg/mL). Each standard solution (10 μL) was infused into the HPLC system, and an assay line was prepared using the peak heights (x) and concentrations (y).
Statistical analysis
Statistical comparisons were made using one−way ANOVA followed by Tukey' s test. P values of ＜0.05 were considered to indicate significance. OCT stability was defined as the maintenance of at least 90％ of the initial OCT concentration 14) .
Results 1 Compatibility study with commercially available preparations
The assay lines showed linearity at 1 to 50 μg/mL. When OCT was mixed with DEX−SBS 0, the percentage of OCT in the sample was 95％ or greater for 10 days after its preparation (96.7％±0.2％).
When OCT was mixed with DEX−SBS 0.5, the percentage of OCT in the sample was 90％ or greater 3 days after its preparation (93.8％
±3.6％). However, the percentage significantly decreased to 85.1％
±2.0％ after 10 days (p＜0.001). When OCT was mixed with DEX−SBS 2.0, the percentage of OCT in the sample was less than 90％ three days after its preparation (89.9％±2.0％), which showed a significant decrease (p＜0.001) ( Table 1, Fig. 2 ). The pH values after preparation ranged from 5.0 to 7.0.
Effect of pH
At a pH value of 4.0, the percentage of OCT in the sample was 95％ or more until 10 days after its preparation (97.7％±7.7％), whereas at a pH value of 7.0, the percentage of OCT was less than 90％ after 3 days (87.6％±8.7％); however, no significant difference was found. At a pH value of 9.0, a significant decrease in the percentage of OCT in the sample was observed 3 days after its preparation (73.9％±5.6％), which was reduced to 68.7％±4.9％ after 10 days (Fig. 3) .
Effect of SBS
When SBS−containing OCT solution was stored at room temperature, the percentage of OCT in the sample significantly decreased to less than 90％ three days after its preparation (84.4％±4.0％, p＜ 0.001, versus the initial concentration). When the solution was stored in a cool place, the percentage of OCT was 90％ or more after 3 days (93.1％±2.5％), but significantly decreased to 78.2％±1.5％ after 10 days (p＜0.001, versus the initial concentration) (Fig. 4) .
Furthermore, the retention time of OCT was 5.4 min. After 10 days The percentage of OCT in the sample was 95 ％ or more until 10 days after its preparation only when it was mixed with sodium bisulphate (SBS)-free Orgadrone Ⓡ (DEX-SBS 0) injection solution. OCT: octreotide acetate, DEX: dexamethasone sodium phosphate, SBS: sodium bisulphate of storage at room temperature in the presence of SBS, chromatograms showed new peaks other than the one corresponding to OCT (Fig. 5) .
Discussion
This is the first study to elucidate the effect of SBS on the stability of OCT, with results revealing that compositional changes in OCT can be avoided by selecting SBS−free DEX preparations. No decrease in the percentage of OCT in the sample was observed for 10 days only when OCT was mixed with an SBS−free DEX preparation. In addition, pH was maintained at less than 7.0 for all of the mixed solutions, suggesting that SBS is an important factor influencing the percentage of OCT in a sample mixed with DEX. Moreover, the experiment in which the effect on OCT was investigated in the presence or absence of SBS also showed that the percentage of OCT in the sample serially decreased only in the presence of SBS, further supporting its involvement.
Several studies have shown that OCT stored in polypropylene syringes in a cool place (3°C) under light−protected conditions was stable for approximately 1 month 14, 15) . However, in the presence of SBS, it was impossible to prevent a decrease in the percentage of OCT in the sample at a pH value of 4.0, which is the pH at which OCT may be the most stable based on the results of our experiments investigating the effect of pH, even when the sample was stored in a cool place under light−protected conditions.
The SBS−related decrease in the percentage of OCT may be associated with disulphide−bond cleavage and peptide hydrolysis. However, according to studies with insulin 8, 16) , the cleavage reactions of disulphide bonds with SBS proceed in the absence of denaturizing agents when inter−peptide−chain bonds are detected. However, intra−chain disulphide bonds, as they are found in OCT, have a cyclic structure.
Therefore, such reactions do not proceed in the absence of denaturizing agents. In addition, chromatograms showed several new peaks, suggesting that SBS promoted the hydrolysis of OCT, not the cleavage reactions of disulphide bonds as the insulin study. Thus, when mixing OCT with DEX preparations, an SBS−free DEX formulation should be used.
In conclusion, SBS−free DEX preparations should be selected when mixing OCT with DEX is necessary. In addition, when OCT is mixed with agents other than DEX preparations, whether the formula is suitable with respect to pH changes and the presence or absence of SBS should be evaluated. In some countries where SBS−free DEX preparations are available, OCT and DEX preparations may be administered as a mixture. Such measures that enable the administration of OCT and DEX as a mixture will decrease the frequency of punctures, which may reduce pain in patients who undergo combination therapy with these drugs. This study provides new information on the possible mechanisms involved in the compatibility of OCT with DEX preparations, and identifies a stable, mixed administration method for OCT and DEX preparations. When SBS-containing OCT solution was stored at room temperature (RT) or in a cool place, the percentage of OCT in the sample significantly decreased to less than 90％ after 3 or 10 days. 
